Travere Therapeutics Advances Sparsentan Study in Pediatric Kidney Diseases

Travere Therapeutics, Inc. ((TVTX)) announced an update on their ongoing clinical study.

Travere Therapeutics, Inc. is conducting a clinical study titled A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases. The study aims to assess the safety, efficacy, and tolerability of sparsentan, focusing on its impact on proteinuria in children with specific kidney conditions over a 108-week period. This research is significant as it targets rare pediatric kidney diseases, potentially offering a new treatment option.

The study is testing sparsentan, an investigational drug administered as an oral suspension or tablet. It is designed to treat various proteinuric glomerular diseases, including Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, and Alport Syndrome.

This Phase 2 study follows a non-randomized, parallel intervention model with no masking, focusing on treatment as its primary purpose. Participants are divided into three experimental groups based on their specific conditions, receiving different dosages of sparsentan.

The study began on July 29, 2021, and is currently recruiting participants. The latest update was submitted on June 6, 2025, indicating ongoing progress. The primary completion and estimated study completion dates are yet to be announced.

The outcome of this study could significantly impact Travere Therapeutics’ stock performance and investor sentiment, especially if sparsentan proves effective. As the company targets a niche market with limited competition, successful results could enhance its market position and attract investor interest.

The study is currently ongoing, with further details available on the ClinicalTrials portal.